Bothell’s BioLife Solutions named to Deloitte 2013 Fast Technology 500

Bothell based BioLife Solutions, Inc. today announced that it has been named to the Deloitte 2013 Fast Technology 500 list of North American innovative, high growth technology companies.

Bothell based BioLife Solutions, Inc. today announced that it has been named to the Deloitte 2013 Fast Technology 500 list of North American innovative, high growth technology companies.

The Deloitte Technology Fast 500 is the pre-eminent technology awards program in United States and Canada with 2013 being its 19th anniversary.

Combining technological innovation, entrepreneurship and rapid growth, Fast 500 companies – large, small, public and private – span a variety of industry sectors, and are leaders in hardware, software, telecom, semiconductors, life sciences and emerging areas, such as clean technology. These companies are on the cutting edge and are transforming the way we do business.

BioLife Solutions is a developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer.

“Being recognized on the Deloitte Fast Technology 500 is a great accomplishment for our entire team,” BioLife Solutions CEO Mike Rice said. “During the last several years, we have worked very hard to build a successful franchise in the high growth regenerative medicine industry, where our HypoThermosol and CryoStor biopreservation media products are now incorporated into 100 hospital-approved and clinical trial stage cell and tissue-based products and therapies that have the potential to revolutionize how the leading causes of death and disorders are treated throughout the world. The next five years hold tremendous potential for BioLife’s revenue and profit growth as our customers complete clinical trials and commence large-scale commercial production of cell and tissue-based products. Our biopreservation IP is embedded in the source material and manufactured doses of these novel regenerative medicine applications, so we’re positioned for high growth and have the capacity to meet future demand for our products.”

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues.

Companies must have 2008 operating revenues of at least $50,000 USD or CD, and 2012 operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.